Molecular Cytology Techs Rising

Cancer testing is shifting toward tools that can read more from less — a key change for cytology, where doctors often work with only a few cells from a needle or fluid sample. (nature.com) Cytology means diagnosing disease from loose cells rather than a chunk of tissue. In a Nature Communications study published January 2, 2025, Memorial Sloan Kettering researchers reported on 4,871 prospectively sequenced clinical cytology samples and said optimized workflows pushed comprehensive profiling success to as high as 93%. (nature.com) That same study found residual supernatant cell-free DNA — tumor DNA left in the fluid around sampled cells — rescued testing in 71% of cases after tumor tissue in the cell block was depleted. The authors also reported low-level cross-contamination in 4.7% of cell block samples, while supernatant DNA showed negligible contamination. (nature.com) One line of work looks beyond DNA to RNA, the short-lived messages cells make from genes. In Cell Reports Medicine, researchers reported that “orphan” cancer RNAs, or oncRNAs, formed binary presence-absence patterns that acted as digital barcodes for cancer type, subtype, and cell state across 32 tumor types. (cell.com) The same paper said some of those oncRNAs are secreted into blood, making part of the barcode accessible through liquid biopsy instead of tissue sampling. In a retrospective breast cancer cohort of 192 patients, the authors reported oncRNAs could be detected in blood and that changes in cell-free oncRNA burden tracked outcomes after neoadjuvant chemotherapy. (cell.com; biorxiv.org) Another line of work focuses on plasma, the cell-free portion of blood, for prostate cancer monitoring. In Nature Communications on February 28, 2024, investigators analyzed 738 plasma samples from 491 men with metastatic castration-resistant prostate cancer and found circulating tumor DNA fraction predicted survival, progression-free survival, and treatment response independent of treatment context. (nature.com) Spatial methods add a map to molecular testing by showing where signals sit inside cells instead of averaging them together. Element Biosciences says its AVITI24 platform combines RNA, protein, morphology, spatial context, and dynamic response in a single assay, with runs under 24 hours and capacity for up to 2 million adherent cells across dual flow cells. (elementbiosciences.com) That kind of spatial readout matters in scant samples because rare tumor cells can be drowned out when everything is blended together. Element says AVITI24 is designed for subcellular co-detection of RNA, protein, and morphology, which could help separate true tumor signals from background cells in mixed specimens. (elementbiosciences.com) Live-cell probes tackle a different problem: seeing tiny structures in intact cells without genetic engineering. In Nature Chemical Biology on April 15, 2026, researchers reported that CenSpark, a cell-permeable fluorescent probe, selectively labels centrioles, cilia, and flagella in live and fixed specimens by targeting the paired microtubule geometry unique to those structures. (nature.com) The authors used CenSpark to measure the rate of primary cilium formation and to track centrioles in chimeric antigen receptor T cells during immune synapse polarization. For cytology labs, the broader direction is clear: more assays are being built to extract tumor identity, variants, and cell behavior from the smallest possible sample. (nature.com; nature.com)